887913-52-2

Basic information

• Product Name: Carbamic acid, N- [(methylamino)thioxomethyl]-, 1,1- dimethylethyl ester
• Synonyms: Carbamic acid, N- [(methylamino)thioxomethyl]-, 1,1- dimethylethyl ester;Carbamic acid, [(methylamino)thioxomethyl]-, 1,1-dimethylethyl ester;tert-butyl N-(methylcarbamothioyl)carbamate;N-Boc-N'-Methyl Thiourea;N-Boc-N-Methyl Thiourea(WX619139);tert-Butyl methylcarbamothioylcarbamate
• CAS NO: 887913-52-2
• Molecular Formula: C₇H₁₄N₂O₂S
• Molecular Weight: 190.26326
• Mol File: 887913-52-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbamic acid, N- [(methylamino)thioxomethyl]-, 1,1- dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, N- [(methylamino)thioxomethyl]-, 1,1- dimethylethyl ester(887913-52-2)
• EPA Substance Registry System: Carbamic acid, N- [(methylamino)thioxomethyl]-, 1,1- dimethylethyl ester(887913-52-2)

Safety Data

• Hazardous Substances Data: 887913-52-2(Hazardous Substances Data)

Upstream product

• 4248-19-5 tert-butyl carbazate 
• 624-83-9 methyl isocyanate 
• 556-61-6 methyl thioisocyanate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 598-52-7 1-(methyl)-thiourea 

Downstream Products

• 1392015-34-7 C₂₉H₃₁N₃O₄ 
• 1392015-33-6 (R)-tert-butyl (4-(3-bromophenyl)-1-methyl-6-oxo-4-phenyltetrahydropyrimidin-2(1H)-ylidene)carbamate 
• 1254199-70-6 (S)-tert-butyl 4-(5-amino-2-fluorophenyl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1H)-ylidenecarbamate 
• 1286278-36-1 (S)-tert-butyl 4-(5-bromo-2-fluorophenyl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1H)-ylidenecarbamate 
• 1254199-54-6 (S)-tert-butyl 4-(2-fluoro-5-nitrophenyl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1H)-ylidenecarbamate 
• 1192479-41-6 C₂₃H₂₇BrN₄O₃S 
• 1125407-02-4 C₁₈H₂₂BrN₃O₃ 
• 1192479-41-6 C₂₃H₂₇BrN₄O₃S 
• 1254199-66-0 [(S)-4-(3-amino-phenyl)-1,4-dimethyl-6-oxo-1,4,5,6-tetrahydro-pyrimidin-2-yl]-carbamic acid tert-butyl ester 

Relevant articles and documents

COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS

The present invention relates to compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X, Y, Z, Q, W, m, u, ring (A), R2, R3, R4, R5 and R6, are as defined in the specification and claims. The present invention provides a pharmaceutical composition containing the compounds of Formula (I) and a therapeutic method of treating and/or preventing Downs syndrome, β-amyloid angiopathy, disorders associated with cognitive impairment, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegenerative diseases, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, Alzheimer's disease and/or Down syndrome, age-related macular degeneration (AMD), glaucoma, olfactory function impairment, traumatic brain injury, progressive muscle diseases, Type II diabetes mellitus and cardiovascular diseases (stroke).

1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS

This invention relates to compounds of the formula wherein R1 to R9 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the therapeutic and/

PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides provides certain pentafluorosulfur imino heterocyclic compounds, including compounds Formula (I): and tautomers thereof, and solvates, prodrugs, esters, and deuterates of said compounds and said tautomers, and pharmaceutically acceptable salts of said compounds, tautomers, solvates, prodrugs, esters, and deuterates, wherein each of R1, R2, R3, R4, R5, R9, R11, ring A, ring B, m, n, p, q, r, -L1-,L2-, and L3- is selected independently and as defined herein. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers Disease, are also disclosed.